Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALLOB in delayed-union fractures
NCT02020590Phase 2Completed
- Sponsor
- BioSenic
- Start
- Feb 2014
- Primary completion
- Sep 2017
- Modality
- Stem Cell Therapies
01
Overview
Phase 2, open-label, single-arm trial of allogeneic osteoblastic cells in Delayed union fracture, sponsored by BioSenic. Primary endpoint: Percentage of Responders at 6 Months. Started Feb 2014; status: completed.
02
Drugs
allogeneic osteoblastic cells
03
Conditions
Delayed union fracture
Beyond the preview
Go deeper on NCT02020590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02020590.